Idenix Restructures, Amends Collaboration with Novartis - - BioPharm International

ADVERTISEMENT

Idenix Restructures, Amends Collaboration with Novartis

BioPharm Bulletin

Idenix Pharmaceuticals, Inc. (Cambridge, MA), has announced a strategic restructuring and an amended collaboration agreement with Novartis Pharma AG related to Sebivo (also marketed as Tyzeka), an oral treatment for patients with chronic hepatitis B.

According to the amended agreement, Idenix will discontinue all development, manufacturing, and commercial activities for Sebivo. Novartis will have full responsibility for ongoing and future clinical trials and regulatory filings related to Sebivo. Idenix will receive a royalty on worldwide product sales. As a result of the changes, Idenix is reducing its workforce of 300 persons by approximately 100 positions, the majority of which support the development and commercialization of Sebivo in the US and Europe.

The changes will allow Idenix to focus on its HCV and HIV programs. Idenix currently has a non-nucleoside reverse transcriptase inhibitor, IDX899, for the treatment of HIV-1, which is being evaluated in Phase 1 and 2 clinical testing. The company also has a comprehensive HCV discovery effort, comprising a next-generation nucleoside polymerase inhibitor program, including IDX102 and IDX184, which are being evaluated in preclinical testing, and HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor programs.

Idenix release

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here